Holen Sie sich die Stockscreener-App
1.5401
0.33%
0.0101
Schlusskurs vom Vortag:
$1.53
Offen:
$1.54
24-Stunden-Volumen:
151.81K
Relative Volume:
0.14
Marktkapitalisierung:
$95.89M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-73.79M
KGV:
-0.837
EPS:
-1.84
Netto-Cashflow:
$-77.44M
1W Leistung:
+12.04%
1M Leistung:
+18.08%
6M Leistung:
-15.66%
1J Leistung:
+43.46%
1-Tages-Spanne:
$1.51
$1.5998
1-Wochen-Bereich:
$1.35
$1.61
52-Wochen-Spanne:
$0.8332
$5.55
Pyxis Oncology Inc Stock (PYXS) Company Profile
Firmenname
Pyxis Oncology Inc
Sektor
Branche
Telefon
(617) 221-9059
Adresse
321 HARRISON AVENUE, BOSTON
Compare PYXS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
1.5401 | 95.26M | 0 | -73.79M | -77.44M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.70 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.79 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
705.66 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.82 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.42 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-03 | Fortgesetzt | Stifel | Buy |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2024-11-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-11-08 | Eingeleitet | Stephens | Overweight |
| 2024-08-08 | Eingeleitet | Stifel | Buy |
| 2024-05-07 | Fortgesetzt | Jefferies | Buy |
| 2024-02-09 | Eingeleitet | BTIG Research | Buy |
| 2024-01-23 | Eingeleitet | Leerink Partners | Outperform |
| 2023-09-05 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-11-02 | Eingeleitet | BofA Securities | Neutral |
| 2021-11-02 | Eingeleitet | Credit Suisse | Outperform |
| 2021-11-02 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Pyxis Oncology Inc Aktie (PYXS) Neueste Nachrichten
Pyxis Oncology Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Pyxis Oncology (PYXS) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
PYXS Technical Analysis & ETF Price Forecast - Intellectia AI
Will Pyxis Oncology Inc stock benefit from M A2025 Growth vs Value & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
PYXS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Can Pyxis Oncology Inc. expand its profit marginsWeekly Trade Review & Low Drawdown Investment Ideas - mfd.ru
PYXS Should I Buy - Intellectia AI
Can Pyxis Oncology Inc. stock hit record highs againWeekly Risk Report & AI Powered Buy/Sell Recommendations - mfd.ru
Street Watch: Can Pyxis Oncology Inc sustain its profitabilityJuly 2025 News Drivers & Fast Gain Stock Tips - baoquankhu1.vn
Can Pyxis Oncology Inc. sustain its profitabilityJuly 2025 Fed Impact & Capital Protection Trade Alerts - mfd.ru
What catalysts could drive Pyxis Oncology Inc. stock higherJuly 2025 Summary & Risk Managed Trade Strategies - mfd.ru
Pyxis Oncology Announces Interim CEO Amid Leadership Transition - The Globe and Mail
Pyxis Oncology (PYXS) taps board member Thomas Civik as interim CEO in leadership shift - Stock Titan
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Pyxis Oncology (PYXS) - The Globe and Mail
Pyxis Oncology appoints Thomas Civik as interim CEO By Investing.com - Investing.com Nigeria
Pyxis Oncology, Inc. Announces Chief Executive Officer Changes, Effective February 3, 2026 - marketscreener.com
Pyxis Oncology names Thomas Civik as interim CEO - marketscreener.com
Pyxis Oncology Appoints Thomas Civik as Interim CEO - citybiz
Pyxis Oncology appoints Thomas Civik as interim CEO - Investing.com
Pyxis Oncology Announces Interim CEO Appointment and - GlobeNewswire
Pyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Update - MarketBeat
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Pyxis Oncology (NASDAQ:PYXS) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Pyxis Oncology (NASDAQ:PYXS) Downgraded by Wall Street Zen to “Sell” - Defense World
Wall Street Zen Upgrades Pyxis Oncology (NASDAQ:PYXS) to “Hold” - Defense World
Wall Street Zen Upgrades Pyxis Oncology (NASDAQ:PYXS) to "Hold" - MarketBeat
Cancer drug developer Pyxis Oncology to join 2 November investor chats - Stock Titan
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff - The Spec
Pyxis Oncology Reports Increased Losses Amid Development Focus - MSN
Returns Recap: How Pyxis Oncology Inc. stock compares to growth peers2025 Fundamental Recap & Low Volatility Stock Recommendations - ulpravda.ru
Aug Action: Will Pyxis Oncology Inc. stock benefit from automationPortfolio Value Report & Precise Swing Trade Alerts - ulpravda.ru
Will Pyxis Oncology Inc. stock benefit from automationJuly 2025 Decliners & Consistent Income Trade Ideas - Улправда
Will Pyxis Oncology Inc. stock gain from government policiesJuly 2025 Final Week & Fast Entry Momentum Trade Alerts - Улправда
Is Pyxis Oncology Inc. stock a dividend growth opportunity2025 Key Lessons & Real-Time Chart Pattern Alerts - Улправда
The $537B Precision Pivot: Why Molecular Monitoring is the New Oncology Standard - The Globe and Mail
After-Hours Gainers: ALXO, GMED, ACRV, And Biotech Peers Rally On Trial Data And Earnings Updates - RTTNews
Pyxis Oncology, Inc.Common Stock (NQ: PYXS - FinancialContent
Is Pyxis Oncology Inc. stock recession proofHead and Shoulders Patterns & Create Your Free Watchlist Instantly - ulpravda.ru
PYXS Stock Price, Forecast & Analysis | PYXIS ONCOLOGY INC (NASDAQ:PYXS) - Chartmill
Pyxis Oncology (NASDAQ:PYXS) versus Kiora Pharmaceuticals (NASDAQ:KPRX) Head to Head Contrast - Defense World
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
PYXS,RPTX Dividends - Finviz
Goosehead Insurance Inc 2OX Stock Analysis and ForecastMomentum Trading Signals & Exceptional Return Capital - earlytimes.in
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Is Pyxis Oncology Inc. stock positioned well for digital economyShort-Term Trading Alerts & Easy Tools to Analyze Your Investment Risk - bollywoodhelpline.com
Pyxis Oncology Inc. (PYXS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Short Interest in Pyxis Oncology, Inc. (NASDAQ:PYXS) Drops By 57.3% - MarketBeat
Pyxis Oncology Stock Plunge: A Buy Signal? - StocksToTrade
Pyxis Oncology Stock Slides 73% With A 7-Day Losing Spree - Trefis
Finanzdaten der Pyxis Oncology Inc-Aktie (PYXS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):